Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response

Cancer Letters

Volumn 278, Issue 1, 2009, Pages 9-16

  Alaniz, Laura ^a,b   Rizzo, Miguel ^a   Malvicini, Mariana ^a   Jaunarena, Jorge ^a   Avella, Diego ^a   Atorrasagasti, Catalina ^a   Aquino, Jorge B ^a   Garcia, Mariana ^a,b,c   Matar, Pablo ^b,d   Silva, Marcelo ^a   Mazzolini, Guilermo ^a,b  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b CONICET ^*  (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Colorectal carcinoma; Dendritic cells; Hyaluronan; MHC class II

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; HIGH MOLECULAR WEIGHT HYALURONIC ACID; HYALURONIC ACID; LOW MOLECULAR WEIGHT HYALURONIC ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL LYSATE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; HISTOPATHOLOGY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MIXED LYMPHOCYTE REACTION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FLOW CYTOMETRY; HYALURONIC ACID; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT;

ANIMALIA; MUS;

EID: 63449101042     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.029     Document Type: Article

References (37)

1. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., and Buchler M.W. Colorectal cancer. Lancet 365 (2005) 153-165
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global Cancer Statistics, 2002, CA. Cancer J. Clin. 55 (2005) 74-108
3. Wolpin B.M., and Mayer R.J. Systemic treatment of colorectal cancer. Gastroenterology 134 (2008) 1296-1310
4. Mazzolini G., Atorrasagasti C., Dubrot J., Tirapu I., Rizzo M., Arina A., Alfaro C., Azpilicueta A., Berasain C., Perez-Gracia J.L., Gonzalez A., and Melero I. Immunotherapy and immunoescape in colorectal cancer. World J. Gastroenterol. 13 (2007) 5822-5831
5. Mosolits S., Ullenhag G., and Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann. Oncol. 16 (2005) 847-862
6. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
7. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 4 (2004) 528-539
8. Jiang D., Liang J., and Noble P.W. Hyaluronan in tissue injury and repair. Ann. Rev. Cell Dev. Biol. 23 (2007) 435-461
9. Ghatak S., Misra S., and Toole B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem. 277 (2002) 38013-38020
10. Bourguignon L.Y.W., Singleton P.A., Zhu H., and Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J. Biol. Chem. 278 (2003) 29420-29434
11. Cordo Russo R., Garcia M.G., Alaniz L., Blanco G., Alvarez E., and Hajos S.E. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int. J. Cancer 122 (2008) 1012-1018
12. Fraser J.R., Laurent T.C., and Laurent U.B. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 242 (1997) 27-33
13. McKee C.M., Penno M.B., Cowman M., Burdick M.D., Strieter R.M., Bao C., and Noble P.W. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. J. Clin. Invest. 98 (1996) 2403-2413
14. McKee C.M., Lowenstein C.J., Horton M.R., Wu J., Bao C., Chin B.Y., Choi A.M.K., and Noble P.W. Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor kappa B-dependent mechanism. J. Biol. Chem 272 (1997) 8013-8018
15. Termeer C., Sleeman J.P., and Simon J.C. Hyaluronan - magic glue for the regulation of the immune response?. Trends Immunol. 24 (2003) 112-114
16. Do Y., Nagarkatti P.S., and Nagarkatti M. Role of CD44 and hyaluronic acid (HA) in activation of alloreactive and antigen-specific T cells by bone marrow-derived dendritic cells. J. Immunother. 27 (2004) 1-12
17. +_regulatory T cells. J. Immunol. 179 (2007) 744-747
18. Ruffell B., and Johnson P. Hyaluronan induces cell death in activated T cells through CD44. J. Immunol. 181 (2008) 7044-7054
19. Itano N., and Kimata K. Altered hyaluronan biosynthesis in cancer progression. Semin. Cancer Biol. 18 (2008) 268-274
20. Ropponen K., Tammi M., Parkkinen J., Eskelinen M., Tammi R., Lipponen P., Agren U., Alhava E., and Kosma V.M. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 58 (1998) 342-347
21. Boregowda R.K., Appaiah H.N., Siddaiah M., Kumarswamy S.B., Sunila S., Thimmaiah K.N., Mortha K.K., Toole B., and Banerjee S. Expression of hyaluronan in human tumor progression. J. Carcinogen. (2006) 10.1186/1477-3163-5-2
22. Misra S., Obeid L.M., Hannun Y.A., Minamisawa S., Berger F.G., Markwald R.R., Toole B.P., and Ghatak S. Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. J. Biol Chem. 23 (2008) 14335-14344
23. Noble P.W. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol. 21 (2002) 25-29
24. Adamia S., Maxwell C.A., and Pilarski L.M. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5 (2005) 3-14
25. Alaniz L., Garcia M.G., Gallo-Rodriguez C., Agusti R., Sterin-Speziale N., Hajos S.E., and Alvarez E. Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-{kappa} B transcription factor. Glycobiology 16 (2006) 359-367
26. Brattain M.G., Strobel-Stevens J., Fine D., Webb M., and Sarrif A.M. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 40 (1980) 2142-2146
27. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., and Strober W. (Eds). Current Protocols in Immunology (1994), John Wiley & Sons, Inc., New York
28. Setton-Avruj C.P., Aquino J.B., Goedelman C.J., Soto E.F., and Villar M.J. P0 and myelin basic protein-like immunoreactivities following ligation of the sciatic nerve in the rat. Neurochem. Res. 27 (2002) 1293-1303
29. Alaniz L., Cabrera P.V., Blanco G., Ernst G., Rimoldi G., Alvarez E., and Hajos S.E. Interaction of CD44 with different forms of hyaluronic acid. Its role in adhesion and migration of tumor cells. Cell Commun. Adhesion 9 (2002) 117-130
30. Talmor M., Mirza A., Turley S., Mellman I., Hoffman L.A., and Steinman R.M. Generation or large numbers of immature and mature dendritic cells from rat bone marrow cultures. Eur. J. Immunol. 28 (1998) 811-817
31. Toole B.P. Hyaluronan promotes the malignant phenotype. Glycobiology 12 (2002) 37R-42
32. Adris S.K., Jasnis M.A., Chuluyan E., Ledda M.F., Bravo A.I., Carbone C., Chernajovsky Y., and Podhajcer O. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther. 6 (1999) 1705-1712
33. Zeng C., Toole B.P., Jing-wen Kuo S.D.K., and Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int. J. Cancer 77 (1998) 396-401
34. Hosono K., Nishida Y., Knudson W., Knudson C.B., Naruse T., Suzuki Y., and Ishiguro N. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am. J. Pathol. 171 (2007) 274-286
35. Mummert M.E. Immunologic roles of hyaluronan. Immunol. Res. 31 (2005) 189-205
36. Mahaffey C.L., and Mummert M.E. Hyaluronan synthesis is required for IL-2-mediated T cell proliferation. J. Immunol. 179 (2007) 8191-8199
37. Termeer C.C., Hennies J., Voith U., Ahrens T., Weiss J.M., Prehm P., and Simon J.C. Oligosaccharides oHyaluronan are potent activators of dendritic cells. J. Immunol. 165 (2000) 1863-1870